Autolus Therapeutics (AUTL) Non Operating Income (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Non Operating Income for 9 consecutive years, with -$19.0 million the latest figure, recorded in Q4 2025.

• Quarterly Non Operating Income fell 138.31% year-over-year to -$19.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.0 million (down 167.35% YoY) and the FY2025 annual result came in at -$15.0 million, down 167.34% from the prior year.
• Non Operating Income declined to -$19.0 million in Q4 2025 per AUTL's latest filing, from -$7.0 million in the prior quarter.
• Over the last five years, Non Operating Income for AUTL reached as high as $49.7 million in Q4 2024 and fell as low as -$23.9 million in Q4 2023.
• A 5-year average of -$1.4 million and a median of -$1.5 million in 2021 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2024 — Non Operating Income plunged 1959.23% — and 2025, when it jumped 1834.6%.
• Year by year, Non Operating Income stood at -$1.0 million in 2021, then surged by 505.09% to $4.2 million in 2022, then slumped by 666.79% to -$23.9 million in 2023, then soared by 307.82% to $49.7 million in 2024, then slumped by 138.31% to -$19.0 million in 2025.
• According to Business Quant data, Non Operating Income over the past three periods registered -$19.0 million, -$7.0 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.